Cargando…
Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt’s lymphoma anti-tumor activity
Tumors frequently display a glycolytic phenotype with increased flux through glycolysis and concomitant synthesis of lactate. To maintain glycolytic flux and prevent intracellular acidification, tumors efflux lactate via lactate transporters (MCT1-4). Inhibitors of lactate transport have the potenti...
Autores principales: | Curtis, Nicola J., Mooney, Lorraine, Hopcroft, Lorna, Michopoulos, Filippos, Whalley, Nichola, Zhong, Haihong, Murray, Clare, Logie, Armelle, Revill, Mitchell, Byth, Kate F., Benjamin, Amanda D., Firth, Mike A., Green, Stephen, Smith, Paul D., Critchlow, Susan E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5642474/ https://www.ncbi.nlm.nih.gov/pubmed/29050199 http://dx.doi.org/10.18632/oncotarget.18215 |
Ejemplares similares
-
Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and Burkitt lymphoma
por: Noble, Richard A., et al.
Publicado: (2017) -
In Vitro and In Vivo Characterization of MCT1 Inhibitor AZD3965 Confirms Preclinical Safety Compatible with Breast Cancer Treatment
por: Benyahia, Zohra, et al.
Publicado: (2021) -
In Vivo Anticancer Activity of AZD3965: A Systematic Review
por: Silva, Ana, et al.
Publicado: (2021) -
Tracing Nutrient Flux Following Monocarboxylate Transporter-1 Inhibition with AZD3965
por: Braga, Marta, et al.
Publicado: (2020) -
Comparative analysis of primary versus relapse/refractory DLBCL identifies shifts in mutation spectrum
por: Greenawalt, Danielle M., et al.
Publicado: (2017)